Eastern Hepatobiliary Surgery Hospital
🇨🇳China
Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Radiation: Stereotactic radiotherapy
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT04891874
- Locations
- 🇨🇳
Second Military Medical University, Shanghai, Shanghai, China
Anti-angiogenic Targeted Drugs Plus Rg3 to Improve the Efficacy of TACE for Unresectable Hepatocellular Carcinoma
Not Applicable
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 320
- Registration Number
- NCT04523467
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis
Phase 2
- Conditions
- Intrahepatic Cholangiocarcinoma Recurrent
- Interventions
- Drug: Neoadjuvant chemotherapy
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04523402
A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
Not Applicable
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 184
- Registration Number
- NCT04521491
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma
Not Applicable
- Conditions
- Portal Vein OcclusionCholangiocarcinoma, PerihilarLiver; Hypertrophy, AcuteHepatocellular Carcinoma
- Interventions
- Procedure: PVE with coils plus TAGMProcedure: PVE with multiple coils
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 56
- Registration Number
- NCT04386772
- Locations
- 🇨🇳
Easter hepatobiliary surgery hospital, Shanghai, Shanghai, China
Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 138
- Registration Number
- NCT03702491
- Locations
- 🇨🇳
xiao qing xiao qing Jiang, Shanghai, Shanghai, China
Prospective Surveillance for Very Early Hepatocellular Carcinoma
- Conditions
- Carcinoma, Hepatocellular
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 10000
- Registration Number
- NCT03588442
- Locations
- 🇨🇳
The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing, Chongqing, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Mengchao Hepatobiliary Surgery Hospital of Fujian Medical University, Fuzhou, Fujian, China
Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma
Phase 4
- Conditions
- Tumor RecurrenceHepatocellular Carcinoma
- Interventions
- Drug: Babaodan oral capsuleDrug: Placebo oral capsule
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 459
- Registration Number
- NCT03515369
Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Diagnostic Test: PIVKA-II
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 4005
- Registration Number
- NCT03047603
- Locations
- 🇨🇳
Eastern hepatobiliary surgery hospital, Shanghai, Shanghai, China
Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion
Not Applicable
Completed
- Conditions
- Recurrent Hepatocellular Carcinoma
- Interventions
- Procedure: TACEProcedure: Hepatectomy
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT02728219
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath